MedTrace Logo

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

NCT01194986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-01-28

No results posted yet for this study

Summary

The purpose of this study is to investigate features of radioligand \[11C\]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.

Conditions

  • Brain Distribution of [11C]AZ12807110 and AZD5213

Interventions

OTHER

[11C]AZ12807110

Radioligand

DRUG

AZD5213

Sponsors & Collaborators

Principal Investigators

  • Björn Paulsson, MD · AstraZeneca

  • Wolfgang Kühn, MD · Quintiles AB, Uppsala

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194986 on ClinicalTrials.gov